Document is current
Any future updates will be listed below
-
Authors
Rafael-Palou, Xavier https://orcid.org/0000-0002-4489-4806
Jimenez-Pastor, Ana
Martí-Bonmatí, Luis
Muñoz-Nuñez, Carlos F.
Laudazi, Mario
Alberich-Bayarri, Ángel
- License Information
-
More Information
Article History
Received: 2 April 2025
Accepted: 16 July 2025
First Online: 18 August 2025
Declarations
:
: This study was conducted according to the ethical principles outlined in the Declaration of Helsinki. Ethics approval was obtained from the following Institutional Review Boards: Comité Ético de Investigación con Medicamentos del Hospital Clínico Universitario de Valencia, approval number 2023/254, approved on July 14, 2023; Comité de Ética de la Investigación con Medicamentos del CEIM—Hospital Universitario y Politécnico La Fe, approval number 2023-317-1, approved on May 12, 2023.
: Written informed consent was waived.
: AA-B is the shareholder and CEO of Quibim. XR-P, AJ-P, LM-B, CFM-N, and ML have no competing interests to declare that are relevant to the content of this article.
